Traneurocin

Traneurocin
Clinical data
Other names	Cycloprolylglycine; Cyclo-Gly-Pro; Cyclo-Pro-Gly; CGP; Cyclo-GP; Biocovax; Biomedivir; Dexaneurosone; NA-831; NA-81; Nanomedivir; Neurosivir; Traneurocine; (S)-Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
Drug class	Neuroprotective; Neurogenesis stimulant; Cognitive enhancer
Pharmacokinetic data
Elimination half-life	7 hours
Identifiers
	IUPAC name (8aS)-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione;
CAS Number	3705-27-9;
PubChem CID	126154;
DrugBank	DB04541;
ChemSpider	112149;
UNII	W7O69J5F2B;
ChEMBL	ChEMBL360216;
Chemical and physical data
Formula	C7H10N2O2
Molar mass	154.169 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H]2C(=O)NCC(=O)N2C1;
	InChI InChI=1S/C7H10N2O2/c10-6-4-8-7(11)5-2-1-3-9(5)6/h5H,1-4H2,(H,8,11)/t5-/m0/s1; Key:OWOHLURDBZHNGG-YFKPBYRVSA-N;

Traneurocin (developmental code name NA-831), also known as cycloprolylglycine (CPG), is a racetam-like drug which is under development for the treatment of COVID-19, Alzheimer's disease, fragile X syndrome, Rett syndrome, major depressive disorder, and other neurological disorders.^[2]^[3]^[4] In the case of COVID-19, it is specifically being developed for treatment of COVID-19-induced neuropathy.^[5]

^ Cite error: The named reference TranTranVu2018 was invoked but never defined (see the help page).
^ "Traneurocin". AdisInsight. Springer Nature Switzerland AG. 25 September 2024. Retrieved 19 October 2024.
^ "Delving into the Latest Updates on Traneurocin with Synapse". Synapse. 19 September 2024. Retrieved 19 October 2024.
^ Gudasheva TA, Grigoriev VV, Koliasnikova KN, Zamoyski VL, Seredenin SB (November 2016). "Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors". Doklady. Biochemistry and Biophysics. 471 (1): 387–389. doi:10.1134/S160767291606003X. PMID 28058675.
^ Cite error: The named reference ChoiChoiKopp2024 was invoked but never defined (see the help page).